MAIA Biotechnology, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by MAIA Biotechnology, Inc. on May 14, 2026. The Company is incorporated in Delaware and its common stock trades on the NYSE American under the symbol "MAIA". The report addresses the termination of a material definitive agreement regarding an At-The-Market (ATM) equity offering.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. However, it discloses specific proceeds from the terminated offering:
- Gross Proceeds Raised: Approximately $5,680,924.
- Shares Sold: 3,116,012 shares of common stock.
- Offering Capacity: The prospectus supplement filed on March 28, 2025, authorized up to $11,200,000 in sales.
Material Changes
On May 14, 2026, the Company suspended sales of its common stock under the At The Market Offering Agreement dated February 14, 2024, with H.C. Wainwright & Co., LLC. The Company provided notice of termination to the Agent, which will become effective 7 business days after May 14, 2026, in accordance with the agreement's terms.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the cessation of the ATM facility. The termination of the sales agreement limits the Company's ability to raise capital through this specific mechanism until a new agreement is executed.
Key Facts for Investor Verification
- Verify the effective date of the termination (7 business days post-May 14, 2026) to confirm when the ATM facility is fully closed.
- Review the Company's current cash position and liquidity needs given the suspension of this capital raise channel.
- Confirm if the Company intends to replace the terminated ATM agreement with a new sales agreement or alternative financing.
- Check subsequent filings for any updates on the status of the remaining $5,519,076 capacity under the original prospectus supplement.